{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:56:51Z","timestamp":1773370611838,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nefroe.2025.501359","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T22:56:26Z","timestamp":1762815386000},"page":"501359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the evaluation and treatment of patients with diabetes and albuminuria. Role of non-steroidal mineralocorticoid antagonism"],"prefix":"10.1016","volume":"45","author":[{"given":"Juan","family":"Pay\u00e1n L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Chinchurreta Capote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Hormigo Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Castilla-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Fern\u00e1ndez Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Espigares Huete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.501359_bib0005","series-title":"IDF Diabetes Atlas","year":"2025"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0015","first-page":"109","article-title":"Prevalencia de diabetes mellitus en 2016 en Espa\u00f1a seg\u00fan la Base de Datos Cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP)Endocrinol Diabetes","volume":"68","author":"Men\u00e9ndez Torre","year":"2021","journal-title":"Nutr (Engl Ed)"},{"issue":"8","key":"10.1016\/j.nefroe.2025.501359_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.semerg.2023.102066","article-title":"Diabetes tipo 2 en Andaluc\u00eda: uso de recursos y coste econ\u00f3mico","volume":"49","author":"Aguirre Rodr\u00edguez","year":"2023","journal-title":"Semergen"},{"issue":"8","key":"10.1016\/j.nefroe.2025.501359_bib0025","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s40620-024-02015-5","article-title":"Finerenone: who should prescribe it for CKD? The physician associate\u2019s perspective","volume":"37","author":"Ness","year":"2024","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0030","first-page":"64","article-title":"Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD study","volume":"35","author":"Ruiz-Garc\u00eda","year":"2023","journal-title":"Clin Investig Arterioscler"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0035","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nefroe.2022.01.008","article-title":"Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain","volume":"41","author":"Escobar","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"issue":"18","key":"10.1016\/j.nefroe.2025.501359_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18189853","article-title":"Cost of type 2 diabetes patients with chronic kidney disease based on real-world data: an observational population-based study in Spain","volume":"18","author":"Us\u00f3-Talamantes","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nefroe.2019.01.007","article-title":"The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem","volume":"39","author":"Ortiz","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"issue":"9854","key":"10.1016\/j.nefroe.2025.501359_bib0050","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.nefroe.2025.501359_bib0055","first-page":"S239","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2025.501359_bib0060","first-page":"1","article-title":"Clinical Practice Guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology","volume":"45","author":"Montero","year":"2025","journal-title":"Nefrologia (Engl Ed)"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0065","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.medcli.2020.10.021","article-title":"Study of the effect of chronic kidney disease on the incidence of cardiovascular events in a native Spanish population","volume":"157","author":"Cancho","year":"2021","journal-title":"Med Clin (Barc)"},{"issue":"9854","key":"10.1016\/j.nefroe.2025.501359_bib0070","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0140-6736(12)61300-2","article-title":"Association of kidney disease measures with poor outcomes","volume":"380","author":"Stevens","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0075","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nefroe.2024.11.011","article-title":"Cardiovascular-kidney-metabolic syndrome definition and its role in the prevention, risk staging, and treatment. An opportunity for the Nephrology","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrologia (Engl Ed)"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501359_bib0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1523-1755.2003.00840.x","article-title":"Pathophysiology of proteinuria","volume":"63","author":"D\u2019Amico","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.nefroe.2025.501359_bib0095","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.501359_bib0100","unstructured":"Vergara Arana A, Martinez Castelao A, Gorriz Teruel JL, de Alvaro Moreno F, Navarro Gonzalez J, Soler Romero MJ, et al. Enfermedad Renal Diabetica: Albuminuria y Progresion. In: Lorenzo V, Lopez Gomez JM (Eds). Nefrologia al dia. ISSN: 2659-2606. [Accessed 4 June 2024]. Available from: https:\/\/www.nefrologiaaldia.org\/292."},{"issue":"4","key":"10.1016\/j.nefroe.2025.501359_bib0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nefroe.2023.09.002","article-title":"Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease","volume":"43","author":"G\u00f3rriz","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.501359_bib0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ckj\/sfz007","article-title":"Clarifying the concept of chronic kidney disease for non-nephrologists","volume":"12","author":"Perez-Gomez","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.501359_bib0115","article-title":"Fisiopatolog\u00eda renal y mecanismos farmacol\u00f3gicos de nefroprotecci\u00f3n","volume":"49 Suppl 1","author":"G\u00f3rriz","year":"2023","journal-title":"Semergen"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.nefroe.2025.501359_bib0125","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin converting- enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0130","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.nefroe.2025.501359_bib0135","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501359_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177654","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0150","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.2337\/db12-1512","article-title":"Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes","volume":"62","author":"Weil","year":"2013","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0155","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.nefroe.2025.501359_bib0160","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.nefroe.2025.501359_bib0165","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"17","key":"10.1016\/j.nefroe.2025.501359_bib0180","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2025.501359_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0190","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501359_bib0195","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0200","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.nefroe.2025.501359_bib0205","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","article-title":"Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation","volume":"18","author":"Heerspink","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","article-title":"The residual cardiorenal risk in type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.nefroe.2025.501359_bib0215","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.nefroe.2025.501359_bib0220","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.nefroe.2025.501359_bib0225","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501359_bib0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0245","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.nefroe.2025.501359_bib0250","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2025.501359_bib0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"23","key":"10.1016\/j.nefroe.2025.501359_bib0260","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.nefroe.2025.501359_bib0265","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0270","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.nefroe.2025.501359_bib0275","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s40620-024-02070-y","article-title":"First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting","volume":"37","author":"Nicholas","year":"2024","journal-title":"J Nephrol"},{"issue":"17","key":"10.1016\/j.nefroe.2025.501359_bib0280","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.3390\/jcm13175107","article-title":"Early clinical experience of finerenone in people with chronic kidney disease and type 2 diabetes in Japan-a multi-cohort study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) platform","volume":"13","author":"Sato","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.nefroe.2025.501359_bib0290","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.nefroe.2025.501359_bib0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.nefroe.2025.501359_bib0300","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0305","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"issue":"10157","key":"10.1016\/j.nefroe.2025.501359_bib0310","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.nefroe.2025.501359_bib0315","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0320","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0325","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.nefroe.2025.501359_bib0330","first-page":"1478","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a game charger in the field?","volume":"14","author":"Doumani","year":"2024","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.501359_bib0345","article-title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or post-transplant diabetes","volume":"36","author":"Mahzari","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"10.1016\/j.nefroe.2025.501359_bib0350","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"Supplement_1","key":"10.1016\/j.nefroe.2025.501359_bib0355","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.501359_bib0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.15747","article-title":"Cardiovascular and non-renal complications of chronic kidney disease: managing risk","volume":"26 Suppl 6","author":"Rossing","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0365","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12882-024-03652-5","article-title":"Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes","volume":"25","author":"Khan","year":"2024","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501359_bib0370","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/joim.20050","article-title":"Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes","volume":"297","author":"Zannad","year":"2025","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.nefroe.2025.501359_bib0375","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2215\/CJN.0000000000000526","article-title":"Reframing chronicity with urgency in chronic kidney disease management","volume":"19","author":"Neuen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.nefroe.2025.501359_bib0380","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cells12151975","article-title":"Slowing the progression of diabetic kidney disease","volume":"12","author":"Blazek","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0385","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MNH.0000000000000844","article-title":"The changing trajectory of diabetic kidney disease","volume":"32","author":"Mistry","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2025.501359_bib0390","article-title":"The evolution of \"pillars of therapy\" to reduce heart failure risk and slow diabetic kidney disease progression","volume":"19","author":"Blazek","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0395","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ndt\/gfac331","article-title":"The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","volume":"38","author":"Agarwal","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"10.1016\/j.nefroe.2025.501359_bib0400","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501359_bib0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ckj\/sfy105","article-title":"Impact of a phone app on nephrology referral","volume":"12","author":"Oliva-Damaso","year":"2018","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.nefroe.2025.501359_bib0410","first-page":"31","article-title":"Gu\u00eda de la Sociedad Espa\u00f1ola de Nefrolog\u00eda sobre ri\u00f1\u00f3n y enfermedad cardiovascular","volume":"26","author":"Mar\u00edn","year":"2006","journal-title":"Versi\u00f3n abreviada Nefrologia"},{"issue":"2","key":"10.1016\/j.nefroe.2025.501359_bib0415","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.semerg.2016.11.009","article-title":"Detecci\u00f3n y clasificaci\u00f3n de la enfermedad renal cr\u00f3nica en Atenci\u00f3n Primaria y la importancia de la albuminuria","volume":"44","author":"Labrador","year":"2018","journal-title":"Semergen"},{"issue":"3","key":"10.1016\/j.nefroe.2025.501359_bib0420","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nefroe.2022.07.003","article-title":"Information and consensus document for the detection and management of chronic kidney disease","volume":"42","author":"Garc\u00eda-Maset","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"issue":"5","key":"10.1016\/j.nefroe.2025.501359_bib0425","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1365-2753.2009.01235.x","article-title":"The association between continuity of care and outcomes: a systematic and critical review","volume":"16","author":"Van Walraven","year":"2010","journal-title":"J Eval Clin Pract"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425001361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425001361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:49:39Z","timestamp":1773330579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2013251425001361"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501359","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the evaluation and treatment of patients with diabetes and albuminuria. Role of non-steroidal mineralocorticoid antagonism","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2025.501359","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501359"}}